High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites

Blood Cancer Journal

Volumn 3, Issue 9, 2013, Pages

  Kraan, W ^a   Horlings, H M ^a   Van Keimpema, M ^a   Schilder Tol, E J M ^a   Oud, M E C M ^a   Scheepstra, C ^a   Kluin, P M ^b   Kersten, M J ^c   Spaargaren, M ^a   Pals, S T ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b Onze Lieve Vrouwe Gasthuis ^*  (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

CD79; DLBCL; Lymphoma; MYD88

Indexed keywords

CD79B ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LATENT MEMBRANE PROTEIN 1; LATENT MEMBRANE PROTEIN 2; MYELOID DIFFERENTIATION FACTOR 88;

ARTICLE; B LYMPHOCYTE; EPSTEIN BARR VIRUS INFECTION; GENE MUTATION; HUMAN; HUMAN TISSUE; LARGE CELL LYMPHOMA; MOLECULAR PATHOLOGY; PHENOTYPE; PREVALENCE; SIGNAL TRANSDUCTION; SOMATIC MUTATION;

EID: 84885337075     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2013.28     Document Type: Article

References (20)

1. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503-511. (Pubitemid 30082188)
2. Staudt LM, Dave S. The biology of human lymphoid malignancies revealed by gene expression profiling. Adv Immunol 2005; 87: 163-208. (Pubitemid 41135900)
3. Lenz G, Davis RE, Ngo VN, Lam L, George TC, Wright GW et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 2008; 319: 1676-1679. (Pubitemid 351432507)
4. Compagno M, Lim WK, Grunn A, Nandula SV, Brahmachary M, Shen Q et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 2009; 459: 717-721.
5. Kato M, Sanada M, Kato I, Sato Y, Takita J, Takeuchi K et al. Frequent inactivation of A20 in B-cell lymphomas. Nature 2009; 459: 712-716.
6. Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010; 463: 88-92.
7. Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim KH et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 2011; 470: 115-119.
8. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275-282. (Pubitemid 38029949)
9. Fonseca R, Habermann TM, Colgan JP, O'Neill BP, White WL, Witzig TE et al. Testicular lymphoma is associated with a high incidence of extranodal recurrence. Cancer 2000; 88: 154-161. (Pubitemid 30027691)
10. Zucca E, Conconi A, Mughal TI, Sarris AH, Seymour JF, Vitolo U et al. Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. J Clin Oncol 2003; 21: 20-27.
11. Schlegel U, Schmidt-Wolf IG, Deckert M. Primary CNS lymphoma: clinical presentation, pathological classification, molecular pathogenesis and treatment. J Neurol Sci 2000; 181: 1-12.
12. Booman M, Douwes J, Glas AM, de Jong D, Schuuring E, Kluin PM. Primary testicular diffuse large B-cell lymphomas have activated B-cell-like subtype characteristics. J Pathol 2006; 210: 163-171. (Pubitemid 44463931)
13. Camilleri-Broet S, Criniere E, Broet P, Delwail V, Mokhtari K, Moreau A et al. A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. Blood 2006; 107: 190-196. (Pubitemid 43053543)
14. Riemersma SA, Jordanova ES, Schop RF, Philippo K, Looijenga LH, Schuuring E et al. Extensive genetic alterations of the HLA region, including homozygous deletions of HLA class II genes in B-cell lymphomas arising in immune-privileged sites. Blood 2000; 96: 3569-3577.
15. Booman M, Szuhai K, Rosenwald A, Hartmann E, Kluin-Nelemans H, de JD et al. Genomic alterations and gene expression in primary diffuse large B-cell lymphomas of immune-privileged sites: the importance of apoptosis and immunomodulatory pathways. J Pathol 2008; 216: 209-217.
16. Gonzalez-Aguilar A, Idbaih A, Boisselier B, Habbita N, Rossetto M, Laurenge A et al. Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas. Clin Cancer Res 2012; 18: 5203-5211.
17. Montesinos-Rongen M, Godlewska E, Brunn A, Wiestler OD, Siebert R, Deckert M. Activating L265P mutations of the MYD88 gene are common in primary central nervous system lymphoma. Acta Neuropathol 2011; 122: 791-792.
18. Pals ST, de Gorter DJ, Spaargaren M. Lymphoma dissemination: the other face of lymphocyte homing. Blood 2007; 119: 2590-2594.
19. de Rooij MF, Kuil A, Geest CR, Eldering E, Chang BY, Buggy JJ et al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood 2012; 119: 2590-2594.
20. Lim KH, Romero DL, Chaudhary D, Robinson SD, Staudt LM. IRAK4 kinase novel therapeutic target in the ABC subtype of diffuse large B cell lymphoma. ASH Annual Meeting Abstracts 2012; 120: 62.